Tukysa

  • April 22, 2020  

    FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 8, 2020  

    Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer

    Smruti Vidwans, PhD

    In 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »